Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-17
2005-05-17
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S279000
Reexamination Certificate
active
06894057
ABSTRACT:
A compound selected from those of formula (I):wherein:X1, X2, and X3, represent N or —CR3in which R3is as described in the description,G1represents a group selected from those of formulae (i/a) and (i/b):in which R4, R5, and R6are as defined in the description,G2represents a group selected from carbon—carbon triple bond, —CH═C═CH—, C═O, C═S, S(O)n1in which n1 represents an integer from 0 to 2 inclusive, or a group of formula (i/c):in which Y1represents O, S, —NH or -Nalkyl, and Y2represents O, S, —NH or -Nalkyl,n is an integer from 0 to 6 inclusive, and m is an integer from 0 to 7 inclusive,Z1represents —CR9R10, wherein R9and R10are as defined in the description,A represents a ring system,R1represents a group selected from H, alkyl, alkenyl, alkynyl, optionally substituted and the group of formula (i/d):in which p, Z2, B, q and G3are as defined in the description and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix mettaloprotease.
REFERENCES:
patent: 4818819 (1989-04-01), Taylor et al.
patent: 4902796 (1990-02-01), Taylor et al.
patent: 5389631 (1995-02-01), Claremon et al.
patent: 5646141 (1997-07-01), Varney et al.
patent: 5925642 (1999-07-01), Ulrich
patent: 5929097 (1999-07-01), Levin et al.
patent: 5948780 (1999-09-01), Peterson, Jr. et al.
patent: 6008243 (1999-12-01), Bender et al.
patent: 6225311 (2001-05-01), Levin et al.
patent: 20020151555 (2002-10-01), Barvian et al.
patent: 20020151558 (2002-10-01), Andrianjara et al.
patent: 20020156061 (2002-10-01), Barvian et al.
patent: 20020156069 (2002-10-01), Picard et al.
patent: 20020161000 (2002-10-01), Barvian et al.
patent: 20030130278 (2003-07-01), Gaudilliere et al.
patent: 20030144274 (2003-07-01), Bunker et al.
patent: 20030216402 (2003-11-01), Gaudilliere et al.
patent: 20030220355 (2003-11-01), Gaudilliere et al.
patent: 20040006077 (2004-01-01), Gaudilliere et al.
patent: 20040034009 (2004-02-01), Roark
patent: 20040034054 (2004-02-01), Wilson
patent: 20040038959 (2004-02-01), Bunker et al.
patent: 20040038960 (2004-02-01), Li
patent: 20040038961 (2004-02-01), Bunker et al.
patent: 20040038973 (2004-02-01), Nahra et al.
patent: 20040038974 (2004-02-01), Ortwine
patent: 20040038994 (2004-02-01), Wilson
patent: 20040039012 (2004-02-01), Wilson
patent: 20040043983 (2004-03-01), Li
patent: 20040043984 (2004-03-01), O'Brien
patent: 20040043985 (2004-03-01), Hicks et al.
patent: 20040043986 (2004-03-01), Nahra et al.
patent: 20040043991 (2004-03-01), Picard et al.
patent: 20040044000 (2004-03-01), Bunker et al.
patent: 20040063673 (2004-04-01), Johnson
patent: 20040142950 (2004-07-01), Bunker et al.
patent: 0935963 (1999-08-01), None
patent: 1138680 (2001-10-01), None
patent: 10195063 (1998-07-01), None
patent: 10195063 (1998-07-01), None
patent: 9616046 (1996-05-01), None
patent: 9816514 (1998-04-01), None
patent: 9826664 (1998-06-01), None
patent: 0009485 (2000-02-01), None
patent: 0035906 (2000-06-01), None
patent: 0040561 (2000-07-01), None
patent: 0044716 (2000-08-01), None
patent: 0045063 (2000-08-01), None
patent: 0112611 (2001-02-01), None
patent: 0155133 (2001-08-01), None
patent: WO 0155133 (2001-08-01), None
patent: 0163244 (2001-08-01), None
patent: 0206513 (2002-01-01), None
patent: 0234726 (2002-05-01), None
patent: 0234753 (2002-05-01), None
patent: 02064080 (2002-08-01), None
patent: 02064547 (2002-08-01), None
patent: 02064568 (2002-08-01), None
patent: 02064571 (2002-08-01), None
patent: 02064572 (2002-08-01), None
patent: 02064578 (2002-08-01), None
patent: 02064595 (2002-08-01), None
patent: 02064598 (2002-08-01), None
patent: 02064599 (2002-08-01), None
patent: WO03032999 (2003-04-01), None
patent: WO03033478 (2003-04-01), None
patent: WO03076417 (2003-09-01), None
patent: WO04000322 (2003-12-01), None
patent: WO04014354 (2004-02-01), None
patent: WO04014365 (2004-02-01), None
patent: WO04014375 (2004-02-01), None
patent: WO04014377 (2004-02-01), None
patent: WO04014378 (2004-02-01), None
patent: WO04014379 (2004-02-01), None
patent: WO04014384 (2004-02-01), None
patent: WO04014388 (2004-02-01), None
patent: WO04014389 (2004-02-01), None
patent: WO04014869 (2004-02-01), None
patent: WO04014880 (2004-02-01), None
patent: WO04014908 (2004-02-01), None
patent: WO04014909 (2004-02-01), None
patent: WO04014916 (2004-02-01), None
patent: WO04014921 (2004-02-01), None
patent: WO04014923 (2004-02-01), None
patent: WO2004014866 (2004-02-01), None
Ramussen et al., Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy, Pharmacol. Ther. vol. 75, No. 1, pp. 69-75, 1997.*
Chambers et al., Review: Changing Views of the Role of Matrix Metalloproteinases in Metastasis, Journal of the National Cancer Institute, vol. 89, No. 17, pp. 1260-1270, Sep. 1997.*
Morris et al., PubMed Abstract (Invasion Metastasis 17(6):281-96), 1997.*
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.*
E.C. Taylor, et al., “Pteridines. 51. A New and Unequivocal Route to C-6 Carbon-Substituted Pterins and Pteridines”, J. Org. Chem. 1987, 52:3997-4000.
E.C. Taylor, et al., “Convergent and Efficient Palladium-Effected Synthesis of 5,10-Dideaza-5,6,7,8-tetrahydrofolic Acid (DDATHF)”, J. Org. Chem. 1989, 52:3618-3624.
M.G. Natchus, et al., “Development of New Carboxylic Acid-Based MMP Inhibitors Derived from Functionalized Propargylglycines”, Journal of Medicinal Chemistry 2001, 44(7):1060-1071.
Derwent Publication Lt. Abstract No. 2001-514548; XP002213435.
A.B. Dyatkin et al., “The Solid Phase Synthesis of Complex Propargylamines Using the Combination of Sonogashira and Mannich Reactions”, Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL 1998, 39(22)3647-3650.
John Montana & Andrew Baxter, “The design of selective non-substrate-based matrix metalloproteinase inhibitors”, Current Opinion in Drug Discovery & Development 2000, 3(4):353-361.
Clark et al., “Matrix metalloproteinase inhibitors in the treatment of arthritis”, Current Opinion in Anti-inflammatory & Immunomodulatory Investigational Drugs 2000, 2(1):16-25.
Chen et al., “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J. Am. Chem. Soc. 2000, 122:9648-9654.
U.S. Appl. No. 10/634,489, filed Aug. 05, 2003, inventor Roark.
U.S. Appl. No. 10/071,032, filed Feb. 08, 2002, inventor Dyer et al.
Chen, et al., “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J. Am. Chem. Soc. 2000, 122-9648-9654.
Lovejoy, et al., “Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors”, Nature Structural Biol., 1999; 6:217-221.
Moy, et al., High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor, J. Mol. Biol., 2000; 302, 671-689.
Mitchell, et al., “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., 1996; 97(3):761-768.
Neuhold, et al., “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice”, J. Clin. Invest., 2001;107: 35-44.
Dahlberg, et al., Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase I (Matrix Metalloproproteinase I) Arthrit & Rheum 2000-A3(3): 673-682.
Billinghurst, et al., “Comparison of the Degradiation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleuken-1 a
Gaudilliere Bernard
Jacobelli Henry
Kostlan Catherine
Li Jack Jie
Yue Wen-Song
Ancona Pamela C.
Pfizer Inc.
Purchase, Jr. Claude F.
Rao Deepak
Warner-Lambert & Company
LandOfFree
Oxo-azabicyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxo-azabicyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxo-azabicyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3386625